Endomorphin-1 and -2 immunoreactive cells in the hypothalamus are labeled by fluoro-gold injections to the ventral tegmental area

Journal of Comparative Neurology

Volumn 454, Issue 3, 2002, Pages 320-328

  Greenwell, Thomas N ^a,b   Zangen, Abraham ^c   Martin Schild, Sheryl ^a,b   Wise, Roy A ^c   Zadina, James E ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Immunocytochemistry; Opioid; Reinforcement; Reward

Indexed keywords

COLCHICINE; ENDOMORPHIN 1; ENDOMORPHIN 2; FLUOROGOLD; OPIATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN PERFUSION; CELL LABELING; CELL SUBPOPULATION; CONTROLLED STUDY; FLUORESCENCE; HYPOTHALAMUS; HYPOTHALAMUS NUCLEUS; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IMMUNOCYTOCHEMISTRY; IMMUNOGOLD LABELING; IMMUNOREACTIVITY; MALE; MICROINJECTION; NERVE CELL NETWORK; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM;

EID: 0037121744     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.10464     Document Type: Article

References (72)

1. Atrens DM. 1973. A reinforcement analysis of rat hypothalamus. Am J Physiol 224:62-65.
2. Beckstead RM, Domesick VB, Nauta WJ. 1979. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res 175:191-217.
3. Bozarth MA. 1987. Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats. Brain Res 414:77-84.
4. Bozarth MA, Wise RA. 1981. Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sci 28:551-555.
5. Bozarth MA, Wise RA. 1982. Localization of the reward-relevant opiate receptors. NIDA Res Monogr 41:158-164.
6. Broekkamp CL, Van den Bogaard JH, Heijnen HJ, Rops RH, Cools AR, Van Rossum JM. 1976. Separation of inhibiting and stimulating effects of morphine on self-stimulation behaviour by intracerebral microinjections. Eur J Pharmacol 36:443-446.
7. Brog JS, Salyapongse A, Deutch AY, Zahm DS. 1993. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 338:255-278.
8. Carlezon WA Jr, Haile CN, Coppersmith R, Hayashi Y, Malinow R, Neve RL, Nestler EJ. 2000. Distinct sites of opiate reward and aversion within the midbrain identified using a herpes simplex virus vector expressing GluR1. J Neurosci 20:RC62.
9. Chavkin C, James IF, Goldstein A. 1982. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215:413-415.
10. Corbett AD, Patterson SJ, Kosterlitz HW. 1993. Opioids I. In: Herz A, editor. Handbook of Experimental Pharmacology. New York: Springer. p 645-679.
11. Dado RJ, Burstein R, Cliffer KD, Giesler GJ Jr. 1990. Evidence that Fluoro-Gold can be transported avidly through fibers of passage. Brain Res 533:329-333.
12. Devine DP, Wise RA. 1994. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci 14:1978-1984.
13. Devine DP, Leone P, Wise RA. 1993. Mesolimbic dopamine neurotransmission is increased by administration of mu-opioid receptor antagonists. Eur J Pharmacol 243:55-64.
14. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
15. Dilts RP, Kalivas PW. 1989. Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res 488:311-327.
16. Dilts RP, Kalivas PW. 1990. Autoradiographic localization of delta opioid receptors within the mesocorticolimbic dopamine system using radioiodinated [2-D-penicillamine, 5-D-penicillamine] enkephalin (1251-DPDPE). Synapse 6:121-132.
17. Fallon JH, Leslie FM, Cone RI. 1985. Dynorphin-containing pathways in the substantia nigra and ventral tegmentum: A double labeling study using combined immunofluorescence and retrograde tracing. Neuropeptides 5:457-460.
18. Garzon M, Pickel VM. 2001. Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area. Synapse 41:311-328.
19. Goeders NE, Lane JD, Smith JE. 1984. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 20:451-455.
20. Gratton A, Wise RA. 1983. Brain stimulation reward in the lateral hypothalamic medial forebrain bundle: Mapping of boundaries and homogeneity. Brain Res 274:25-30.
21. Guillery RW. 1957. Degeneration in the hypothalamic connexions of the albino rat. J Anat (Lond) 91:91-115.
22. Herz A. 1997. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129:99-111.
23. Howard CV, Reed MG. 1998. Unbiased Stereology: Three Dimensional Measurement in Microscopy. New York: Springer-Verlag.
24. Ikemoto S, Murphy JM, McBride WJ. 1997. Self-infusion of GABA(A) antagonists directly into the ventral tegmental area and adjacent regions. Behav Neurosci 111:369-380.
25. Johnson SW, North RA. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488.
26. Johnson RP, Sar M, Stumpf WE. 1980. A topographic localization of enkephalin on the dopamine neurons of the rat substantia nigra and ventral tegmental area demonstrated by combined histofluorescenceimmunocytochemistry. Brain Res 194:566-571.
27. Kalivas PW, Churchill L, Klitenick MA. 1993. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57:1047-1060.
28. Khachaturian H, Lewis ME, Watson SJ. 1983. Enkephalin systems in diencephalon and brainstem of the rat. J Comp Neurol 220:310-320.
29. Khachaturian H, Lewis ME, Tsou K, Watson SJ. 1985. Beta-endorphin, alpha-MSH, ACTH, and related peptides. In: Bjorklund A, Hokfelt T, editors. Handbook of Chemical Neuroanatomy. Vol. 4. GABA and Neuropeptides in the CNS. Part I. Amsterdam: Elsevier Science. p 216-250.
30. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. 1977. Endogenous opioid peptides: Multiple agonists and receptors. Nature 267:495-499.
31. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. 1987. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7:2445-2464.
32. Mansour A, Fox CA, Akil H, Watson SJ. 1995a. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci 18:22-29.
33. Mansour A, Watson SJ, Akil H. 1995b. Opioid receptors: Past, present and future. Trends Neurosci 18:69-70.
34. Martin-Schild S, Zadina JE, Gerall AA, Vigh S, Kastin AJ. 1997. Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18:1641-1649.
35. Martin-Schild S, Gerall AA, Kastin AJ, Zadina JE. 1998. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides 19:1783-1789.
36. Martin-Schild S, Gerall AA, Kastin AJ, Zadina JE. 1999. Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 405:450-471.
37. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. 1996. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
38. Moga MM, Saper CB. 1994. Neuropeptide-immunoreactive neurons projecting to the paraventricular hypothalamic nucleus in the rat. J Comp Neurol 346:137-150.
39. Mucha RF, Millan MJ, Herz A. 1985. Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin. Psychopharmacology (Berl) 86:281-285.
40. Narita M, Ozaki S, Ioka M, Mizoguchi H, Nagase H, Tseng LF, Suzuki T. 2001. Different motivational effects induced by the endogenous muopioid receptor ligands endomorphin-1 and -2 in the mouse. Neuroscience 105:213-218.
41. Oades RD, Halliday GM. 1987. Ventral tegmental (A10) system: Neurobiology. 1. Anatomy and connectivity. Brain Res 434:117-165.
42. Olds ME. 1982. Reinforcing effects of morphine in the nucleus accumbens. Brain Res 237:429-440.
43. Olds J, Milner PM. 1954. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47:419-427.
44. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. New York: Academic Press.
45. Phillips AG. 1984. Brain reward circuitry: A case for separate systems. Brain Res Bull 12:195-201.
46. Phillips AG, LePiane FG. 1980. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol Biochem Behav 12:965-968.
47. Phillipson OT. 1978. Afferent projections to A10 dopaminergic neurons in the rat as shown by the retrograde transport of horseradish peroxidase. Neurosci Lett 9:353-359.
48. Phillipson OT. 1979. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxidase study in the rat. J Comp Neurol 187:117-143.
49. Pickel VM, Chan J, Sesack SR. 1993. Cellular substrates for interactions between dynorphin terminals and dopamine dendrites in rat ventral tegmental area and substantia nigra. Brain Res 602:275-289.
50. Pierce TL, Wessendorf MW. 2000. Immunocytochemical mapping of endomorphin-2-immunoreactivity in rat brain. J Chem Neuroanat 18: 181-207.
51. Pierce TL, Grahek MD, Wessendorf MW. 1998. Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport 9:385-389.
52. Sar M, Stumpf WE, Miller RJ, Chang KJ, Cuatrecasas P. 1978. Immunohistochemical localization of enkephalin in rat brain and spinal cord. J Comp Neurol 182:17-37.
53. Schmued LC, Fallon JH. 1986. Fluoro-Gold: A new fluorescent retrograde axonal tracer with numerous unique properties. Brain Res 377:147-154.
54. Schreff M, Schulz S, Wilborny D, Hollt V. 1998. Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport 9:1031-1034.
55. Sesack SR, Pickel VM. 1992. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: Multiple substrates for opiate-dopamine interactions. J Neurosci 12:1335-1350.
56. Sesack SR, Pickel VM. 1995. Ultrastructural relationships between terminals immunoreactive for enkephalin, GABA, or both transmitters in the rat ventral tegmental area. Brain Res 672:261-275.
57. Shippenberg TS, Bals-Kubik R, Herz A. 1987. Motivational properties of opioids: Evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res 436:234-239.
58. Simmons JM, Ackermann RF, Gallistel CR. 1998. Medial forebrain bundle lesions fail to structurally and functionally disconnect the ventral tegmental area from many ipsilateral forebrain nuclei: Implications for the neural substrate of brain stimulation reward. J Neurosci 18:8515-8533.
59. Spanagel R, Herz A, Shippenberg TS. 1990. Identification of the opioid receptor types mediating beta-endorphin-induced alterations in dopamine release in the nucleus accumbens. Eur J Pharmacol 190:177-184.
60. Spanagel R, Herz A, Shippenberg TS. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:2046-2050.
61. Wamsley JK, Young WS III, Kuhar MJ. 1980. Immunohistochemical localization of enkephalin in rat forebrain. Brain Res 190:153-174.
62. Wilson AM, Soignier RD, Zadina JE, Kastin AJ, Nores WL, Olson RD, Olson GA. 2000. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 21:1871-1874.
63. Wise RA. 1989. Opiate reward: Sites and substrates. Neurosci Biobehav Rev 13:129-133.
64. Wise RA. 1998. Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13-22.
65. Wise RA, Bozarth MA. 1982. Action of drugs of abuse on brain reward systems: An update with specific attention to opiates. Pharmacol Biochem Behav 17:239-243.
66. Wise RA, Hoffman DC. 1992. Localization of drug reward mechanisms by intracranial injections. Synapse 10:247-263.
67. Zadina JE, Kastin AJ, Ge DJ, Hackler L. 1994. Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W- MIF-1, its active fragments, and two potent analogs. Life Sci 55:L461-L466.
68. Zadina JE, Hackler L, Ge LJ, Kastin AJ. 1997. A potent and selective endogenous agonist for the mu-opiate receptor [see comments]. Nature 386:499-502.
69. Zadina JE, Martin-Schild S, Gerall AA, Kastin AJ, Hackler L, Ge DJ, Zhang X. 1999. Endomorphins: Novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density. Ann N Y Acad Sci 897:136-144.
70. Zadina JE, Zangen A, Greenwell TN, Martin-Schild S, Wise RA. 2001. Endomorphin-1 and -2 immunoreactive cells in the hypothalamus are labeled by Fluoro-Gold injections in the ventral tegmental area. Soc Neurosci Abstr 27:907.19.
71. Zangen A, Ikemoto S, Zadina JE, Wise RA. 2002. Rewarding and psychomotor stimulant effects of endomorphin-1: Anterior-posterior differences within the ventral tegmental area and lack of effect in nucleus accumbens. J Neurosci 22:7225-7233.
72. Zappone CA, Sloviter RS. 2001. Commissurally projecting inhibitory interneurons of the rat hippocampal dentate gyrus: A colocalization study of neuronal markers and the retrograde tracer Fluoro-Gold. J Comp Neurol 441:324-344.